Local tissue factor pathway inhibitor release in the human forearm

 

 Buy Article Permissions and Reprints

Summary

Nineteen healthy men received unilateral brachial artery infusions of either unfractioned heparin (0.3-100 IU/min), saline or the endothelium-dependent vasodilators substance P (2-8 pmol/min) and bradykinin (100-1000 pmol/min), and the endothelium-independent vasodilator sodium nitroprusside (2-8 µg/min). Heparin caused a dose-dependent increase in plasma TFPI concentrations in both arms (ANOVA, p <0.0001). Estimated net forearm TFPI release was 7 ± 16, 29 ± 20 and 138 ± 72 ng/100 mL tissue/min during 10, 30 and 100 IU/min of heparin respectively (ANOVA, p <0.0001). Compared to the systemic circulation, the forearm sensitivity to heparin induced TFPI release was 3.6-fold lower (166 ± 67 ng/IU vs. 596 ± 252 ng/IU: t-test, p = 0.004). Substance P, bradykinin and sodium nitroprusside all caused substantial dose-dependent increases in blood flow (ANOVA, p <0.001 for all) without affecting plasma TFPI concentrations. There are important regional differences in endothelial TFPI release, with the forearm circulation being relatively insensitive to heparin.

• References

• 1 Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arterioscler Thromb Vasc Biol 2002; 22: 539-48.
  CrossrefPubMedGoogle Scholar
• 2 Crawley J. et al Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 2000; 20: 1362-73.
  CrossrefPubMedGoogle Scholar
• 3 Broze Jr. GJ. et al Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1994; 5: 551-9.
  PubMedGoogle Scholar
• 4 Soejima H. et al Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999; 99: 2908-13.
  CrossrefPubMedGoogle Scholar
• 5 Taubman MB. et al Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost 1997; 78: 200-4.
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 Wilcox JN. et al Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-43.
  CrossrefPubMedGoogle Scholar
• 7 Abendschein DR. et al Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation 1995; 92: 944-9.
  CrossrefPubMedGoogle Scholar
• 8 Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000; 28: S31-S33.
  CrossrefPubMedGoogle Scholar
• 9 Rao AK. et al Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes 1999; 48: 1156-61.
  CrossrefPubMedGoogle Scholar
• 10 Idell S. Extravascular coagulation and fibrin deposition in acute lung injury. New Horiz 1994; 2: 566-74.
  PubMedGoogle Scholar
• 11 Tipping PG. et al Glomerular tissue factor expression in crescentic glomerulonephritis. Correlations between antigen, activity, and mRNA. Am J Pathol 1995; 147: 1736-48.
  PubMedGoogle Scholar
• 12 Sakkinen PA. et al Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort. Thromb Haemost 1998; 80: 134-9.
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997; 78: 471-7.
  Article in Thieme ConnectPubMedGoogle Scholar
• 14 Kojima T. et al Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor. J Cardiothorac Vasc Anesth 2001; 15: 60-4.
  CrossrefPubMedGoogle Scholar
• 15 Badimon JJ. et al Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99: 1780-7.
  CrossrefPubMedGoogle Scholar
• 16 Roque M. et al Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty. J Am Coll Cardiol 2000; 36: 2303-10.
  CrossrefPubMedGoogle Scholar
• 17 Carr C. et al Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock 1994; 44: 126-37.
  PubMedGoogle Scholar
• 18 Westmuckett AD. et al Fluid flow induces upregulation of synthesis and release of tissue factor pathway inhibitor in vitro. Arterioscler Thromb Vasc Biol 2000; 20: 2474-82.
  CrossrefPubMedGoogle Scholar
• 19 Grabowski EF. et al Shear stress decreases endothelial cell tissue factor activity by augmenting secretion of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2001; 21: 157-62.
  CrossrefPubMedGoogle Scholar
• 20 Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-13.
  CrossrefPubMedGoogle Scholar
• 21 Giraux JL, Tapon-Bretaudiere J, Matou S, Fischer AM. Fucoidan, as heparin, induces tissue factor pathway inhibitor release from cultured human endothelial cells. Thromb Haemost 1998; 80: 692-5.
  Article in Thieme ConnectPubMedGoogle Scholar
• 22 Kemme MJ, Burggraaf J, Schoemaker RC. et al The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitor. Clin Pharmacol Ther 2000; 67: 504-11.
  CrossrefPubMedGoogle Scholar
• 23 Webb DJ. The pharmacology of human blood vessels in vivo. J Vasc Res 1995; 32: 2-15.
  CrossrefPubMedGoogle Scholar
• 24 Newby DE. et al An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost 1997; 78: 1242-8.
  Article in Thieme ConnectPubMedGoogle Scholar
• 25 Alban S, Gastpar R. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins. Thromb Haemost 2001; 85: 824-9.
  Article in Thieme ConnectPubMedGoogle Scholar
• 26 Labinjoh C. et al Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. J Am Coll Cardiol 2001; 38: 1402-8.
  CrossrefPubMedGoogle Scholar
• 27 Labinjoh C. et al Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man. Cardiovasc Res 2000; 47: 707-14.
  CrossrefPubMedGoogle Scholar
• 28 Kemme MJ. et al Quantification of heparin induced TFPI release: a maximum release at low heparin dose. Br J Clin Pharmacol 2002; 54: 627-34.
  CrossrefPubMedGoogle Scholar
• 29 Stein CM. et al Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent ago-nists in human vasculature. J Am Coll Cardiol 1998; 32: 117-22.
  CrossrefPubMedGoogle Scholar
• 30 Nilius B, Droogmans G. Ion channels and their functional role in vascular endothelium. Physiol Rev 2001; 81: 1415-59.
  CrossrefPubMedGoogle Scholar
• 31 de Boer A. et al Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise. Thromb Haemost 1992; 68: 550-5.
  Article in Thieme ConnectPubMedGoogle Scholar
• 32 Piatti PM. et al Effects of low-dose heparin infusion on arterial endothelin-1 release in humans. Circulation 1996; 94: 2703-7.
  CrossrefPubMedGoogle Scholar
• 33 Tangphao O. et al Heparin-induced vasodilation in human hand veins. Clin Pharmacol Ther 1999; 66: 232-8.
  CrossrefPubMedGoogle Scholar
• 34 Yokokawa K, Tahara H, Kohno M. et al Heparin regulates endothelin production through endothelium-derived nitric oxide in human endothelial cells. J Clin Invest 1993; 92: 2080-5.
  CrossrefPubMedGoogle Scholar